The Food and Drug Administration (FDA) approved a new "first-in-class" medication to help manage attention deficit ...

The FDA has approved Simtriyo, a nonstimulant daily pill for ADHD in children, teens, and adults. Here’s more on potential ...

Experts are calling for changes to ADHD care as new research raises questions about medication safety.

An 18-year sibling-design study in Psychiatry Research finds that childhood ADHD more than doubles adult depression risk and ...

Once believed to be a condition that children outgrow, attention deficit hyperactivity disorder (ADHD) is now recognized as a ...

New research reveals ADHD isn't one-size-fits-all — covering social media's specific role, why medication rarely 'stops ...

The FDA has approved Simtriyo (centanafadine) as the first norepinephrine, dopamine, serotonin reuptake inhibitor for adult and pediatric ADHD.

For decades, ADHD was viewed as a childhood condition that mostly affected boys. Researchers now know ADHD manifests ...

An eight-week randomized trial of 66 women found that adjunctive vitamin D did not significantly or meaningfully improve ...

The FDA has approved Simtriyo (centanafadine), a first-in-class NDSRI and CNS stimulant, for adult and pediatric ADHD aged 6 years and older.

Understood reports that the FDA has approved Simtriyo, a new ADHD medication targeting dopamine, norepinephrine, and ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of ...